MBRX earnings date and last-quarter result: last quarter miss, P/E -0.07. Updated 2026-07-23.
Moleculin Biotech (MBRX) Research Hub
Moleculin Biotech (MBRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 7.09 USD (+9.08%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.07, market cap 0.01B. This hub links to the full technical, earnings and options research available for MBRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.09 USD (+9.08%) |
| 52-week range | 0.221 USD – 7.25 USD |
| Trend regime | Range |
| 14-day RSI | 91.9 (Overbought) |
| Trailing P/E | -0.07 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
Available research for MBRX
Covered Call on MBRX: how it works, illustrative setup around the real 7.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MBRX: how it works, illustrative setup around the real 7.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MBRX: how it works, illustrative setup around the real 7.09 USD price, max profit/loss, breakeven and when to use it. Educational.
MBRX technical analysis: range, last 7.09 USD, RSI 91.9, 52w range 0.221 USD–7.25 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is MBRX in?
Moleculin Biotech (MBRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MBRX in an uptrend or downtrend?
As of 2026-10-26, MBRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MBRX's trailing P/E ratio?
MBRX's trailing P/E is -0.07, with a market cap of 0.01B. See the earnings research page for full valuation detail.